In Vivo Engineering of Therapeutic Cells Summit

Memo

Join the In Vivo Engineering of Therapeutic Cells Summit to Discover the Future of Cell and Gene Therapy!In vivo gene engineering is fast becoming known as the future of cell and gene therapy with incredible amounts of investment seen in 2021, including the recent Moderna and Metagenomi collaboration alongside the partnership between Abintus Bio and MSKCC, and Tidal acquisition by Sanofi.This game-changing approach promises to replace current ex vivo cell and gene therapies due to their potential ability to directly engineer target cells and remove the need for costly and labor-intensive manufacturing processes.Not only is this the next frontier of cell and gene therapies, but it also reaps the benefits of autologous therapies by targeting the patients' own cells, potentially overcoming common challenges with persistence and durability.Join the In Vivo Engineering of Therapeutic Cells Summit to be brought up to speed on the revolutionary advances in payload delivery in cell and gene therapy. Learn from industry pioneers from Sana Biotechnology, Umoja Biopharma, Beam Therapeutics and Capstan Therapeutics to improve efficacy by reaching a significant number of target cells - including immune cells, liver cells and hematopoietic stem cells, ensuring tolerability for safe dosing strategies, and the considerations for the most optimal in vivo delivery modality comparing viral vectors, mRNA, or non-viral LNPs.Whether your team is ahead of the curve and currently pursuing this approach, or if you are looking to learn more about the space to determine how to advance your current pipelines, don't miss out on this cutting-edge conference to brainstorm best-in-class approaches to accelerate the clinical translation of this next-generation approach.Unite with the greatest minds of the cell and gene field in person this July to ensure your pipeline remains at the forefront of innovative drug development.https://in-vivo-engineering.com/July 12-14, 2022Boston, MAContact:This email address is being protected from spambots. You need JavaScript enabled to view it.:Brochure: https://go.evvnt.com/1038825-0?pid=5569Tickets: https://go.evvnt.com/1038825-1?pid=5569Prices:Drug Developers (Earlybird rates and workshops available): USD 2999.0,Academic (Earlybird rates and workshops available): USD 2599.0,Service Providers (Earlybird rates and workshops available): USD 3599.0Speakers: Adrian Bot, Chief Scientific Officer and Executive Vice President of R and D, Capstan Therapeutics, Andy Scharenberg, Chief Executive Officer, Umoja Biopharma, Cory Bentley, Co-Founder and Senior Vice President of R and D, Abintus Bio, Phil Johnson, Chief Executive Officer, Interius BioTherapeutics, Steve Harr, President and Chief Executive Officer, Sana BiotechnologyDate and Time: On Tuesday July 12, 2022 at 8:00 am (ends Thursday July 14, 2022 at 5:30 pm)Venue Details: Hyatt Regency Boston, 1 Avenue de Lafayette, Boston, Massachusetts, 02111, United States